Diseases · Entity Annotation Prototype (beta)

18articles mentioning diseases

48disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: HIV-RNA ×

HIV-RNA

This disease is selected. Its supporting articles are shown below.

HIV-RNA18

Articles mentioning HIV-RNA

18 articles · page 2 of 2

OC41 Long-term follow-up to 96 weeks of long-acting cabotegravir/rilpivirine: sustained reduction of immune activation and senescence in people living with HIV and CMV co-infection

sextrans · abstract · 2026-06-05 · 1 matching annotations

83.8%

HIV PWH-CG HIV-RNA PWH PWH-LA cabotegravir/rilpivirine CAB/RPV-LA ART

…ite the effectiveness of combined antiretroviral therapy (ART), HIV infection remains a chronic condition characterized by persiste…

OC53 Long-acting cabotegravir/rilpivirine beyond viral suppression: effects on HIV reservoir, immune activation and senescence

sextrans · abstract · 2026-06-05 · 1 matching annotations

89.3%

HIV HIV-DNA HIV-RNA Umberto I hospital of Rome cabotegravir/rilpivirine

…chronically characterize PLWH. Nevertheless, careful monitoring HIV drug resistance, as well as anthropometric factors such as BMI,…

P50 From guidelines to clinical practice: lung cancer screening adherence, preliminary data from the modena HIV cohort

sextrans · abstract · 2026-06-05 · 1 matching annotations

75.9%

PLWH NADCs HIV-RNA HIV Modena HIV Clinic

…ractice.Methods This single-centre retrospective study included PLWH aged ≥18 years actively followed at the Modena HIV Clinic (Mode…

SC34 12 months effectiveness and safety of switching to BIC/FTC/TAF in virologically suppressed people with HIV on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL study)

sextrans · abstract · 2026-06-05 · 1 matching annotations

90.6%

PWH HIV HIV-RNA Gilead Sciences tenofovir alafenamide emtricitabine bictegravir ASST Fatebenefratelli Sacco

…opriate option for optimizing regimens in treatment experienced PWH.This study is sponsored by Gilead Sciences.Abstract SC34 Figure…

SC5 First delivery of long-acting injectable (CAB-LA) pre-exposure prophylaxis (PrEP) in a community-based setting

sextrans · abstract · 2026-06-05 · 1 matching annotations

82.9%

Gonorrhoea Chlamydia HIV HIV-RNA syphilis HIV-prevention CAB-LA cabotegravir CBS PrEP

…V and syphilis rapid test and pooled sampling for Chlamydia and Gonorrhoea were performed at CBS; blood for HIV-RNA was collected at CBS a…

SC22 Life after long-acting therapy: what happens when CAB/RPV is discontinued?

sextrans · abstract · 2026-05-20 · 1 matching annotations

80.7%

VF HIV PWH HIV-RNA SCOLTA cabotegravir+rilpivirine

….9% (15/65), and 84.1% (37/44) of PWH who interrupted LA due to VF, due to any cause other than VF, and due to AEs, respectively. …

Browse diseases

HIV-RNA

Articles mentioning HIV-RNA

OC41 Long-term follow-up to 96 weeks of long-acting cabotegravir/rilpivirine: sustained reduction of immune activation and senescence in people living with HIV and CMV co-infection

OC53 Long-acting cabotegravir/rilpivirine beyond viral suppression: effects on HIV reservoir, immune activation and senescence

P50 From guidelines to clinical practice: lung cancer screening adherence, preliminary data from the modena HIV cohort

SC34 12 months effectiveness and safety of switching to BIC/FTC/TAF in virologically suppressed people with HIV on any ARV-regimens including NNRTIs: a retrospective analysis (ESSENTIAL study)

SC5 First delivery of long-acting injectable (CAB-LA) pre-exposure prophylaxis (PrEP) in a community-based setting

SC22 Life after long-acting therapy: what happens when CAB/RPV is discontinued?